glp-1 shortage news today november 2025 trends 2025: real-world data, patient outcomes & future therapies A 72-week trial compared the

ECC5004/AZD5004 (AstraZeneca/Eccogene) and several Chinese programs are not far behind (see, e.g., here and here)

Second, SGLT2 inhibitors were shown to have the greatest cardiovascular and all-cause mortality benefits amongst all three new antidiabetic drug classes

Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease

In June, the European Medicines Agencys safety committee classified NAION as a very rare side effect of semaglutide drugs and recommended updated warning labels

Table of Contents: How quickly does Semaglutide start suppressing appetite

reimbursed chronic disease), GLP-1 stakeholders must recalibrate go-to-market models by balancing reimbursement strategy, innovation, brand equity and execution speed before competition closes the window